Margaret Embry
Family · Oxford, MSNPI 1386843407
Payments from drug & device makers
Across 273 payments — averaging $19.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$470
- Novo Nordisk$432
- Abbott$383
- Corcept Therapeutics$361
- Lilly USA, LLC$350
- Xeris Pharmaceuticals, Inc.$349
- plus $3K from 30 others
What the payments were for
- Food & beverage$5,210100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 32 | $470 |
| Novo Nordisk | 19 | $432 |
| Abbott | 11 | $383 |
| Corcept Therapeutics | 18 | $361 |
| Lilly USA, LLC | 21 | $350 |
| Xeris Pharmaceuticals, Inc. | 20 | $349 |
| Sequel Med Tech, LLC | 7 | $301 |
| Novartis | 20 | $276 |
| AbbVie | 18 | $256 |
| Amgen(2 entities) | 15 | $256 |
| Dexcom, Inc. | 16 | $249 |
| Recordati_rare_diseases_inc. | 9 | $194 |
| Insulet Corporation | 6 | $193 |
| Medtronic | 6 | $177 |
| Johnson & Johnson | 6 | $106 |
| IBSA Pharma Inc. | 4 | $92 |
| Bayer | 5 | $87 |
| Tandem Diabetes Care, Inc. | 5 | $86 |
| Sanofi-aventis U.S. LLC | 4 | $69 |
| Amarin Pharma, Inc. | 4 | $64 |
| Pfizer | 5 | $64 |
| AstraZeneca | 4 | $52 |
| Kyowa Kirin, Inc. | 2 | $48 |
| Mannkind Corporation | 2 | $43 |
| Antares Pharma, Inc. | 2 | $38 |
| Daiichi Sankyo Inc. | 2 | $30 |
| Ionis Pharmaceuticals, Inc. | 1 | $27 |
| Chiesi USA, Inc. | 1 | $22 |
| Eyevance Pharmaceuticals LLC | 1 | $22 |
| Boston Scientific | 1 | $21 |
| Madrigal Pharmaceuticals | 1 | $19 |
| Edwards Lifesciences | 1 | $19 |
| Averitas Pharma Inc. | 1 | $18 |
| Merck | 1 | $12 |
| GSK | 1 | $11 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FREESTYLE LIBRE 3$250
- TWIIST$147
- Ozempic$107
How this compares
$5,210 in reported general payments places this provider in the 90th percentile of 3,007 family providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 265 | $298,176 |
| MounjaroTirzepatide | 195 | $259,870 |
| JardianceEmpagliflozin | 328 | $257,155 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 105 | $84,629 |
| Tresiba Flextouch U-200Insulin Degludec | 86 | $64,509 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 61 | $56,577 |
| FarxigaDapagliflozin Propanediol | 75 | $50,386 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 60 | $45,452 |
| Gvoke Hypopen 2-PackGlucagon | 59 | $36,794 |
| TradjentaLinagliptin | 50 | $30,703 |
| TrulicityDulaglutide | 22 | $28,379 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 25 | $25,613 |
| Novolog FlexpenInsulin Aspart | 96 | $18,646 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 17 | $17,637 |
| Tresiba Flextouch U-100Insulin Degludec | 36 | $16,880 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Trijardy Xr | $470 | $380,058496 claims |
| Novo NordiskOzempic, Novolog | $432 | $301,152277 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog Mix 75-25 | $350 | $292,819230 claims |
| AstraZenecaFarxiga | $52 | $50,38675 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $69 | $12,55213 claims |
| MerckJanumet Xr | $12 | $3,38314 claims |
| AbbVieSynthroid | $256 | $2,58646 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,007 family providers in Mississippi.
Other family in Oxford
- Shannon FryeryOxford$127K
- Penny BurchamOxford$22K
- Anna WiygulOxford$15K
- Erin SmithOxford$13K
- Cinda PerrymanFayette$888K
- Dodie McGeeRaymond$772K
- Gina BurgeJackson$237K
- Christy DavisJackson$208K
- Maranda EversollFlowood$197K
- Dana DelaskiJackson$158K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.